Fluoxetine and imipramine: Are there differences in cost-utility for depression in primary care?

Journal of Evaluation in Clinical Practice

Volumn 15, Issue 1, 2009, Pages 195-203

  Serrano Blanco, Antoni ^a,b,c   Suárez, David ^b,d   Pinto Meza, Alejandra ^b,c   Peñarrubia, Maria T ^e   Haro, Josep Maria ^b  

^a Sant Joan de Déu Serveis de Salut Mental   (Spain)

^b Centre de Salut Mental El Prat   (Spain)

^c RedIAPP Primary Care Research Network   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e Care Health Center Gavà II   (Spain)

Author keywords

Clinical research; Cost utility analysis; Depression; Economic analysis; Primary health care

Indexed keywords

FLUOXETINE; IMIPRAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSTHYMIA; EUROPEAN QUALITY OF LIFE QUESTIONNAIRE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPAIN; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COSTS AND COST ANALYSIS; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; QUESTIONNAIRES;

EID: 60349110310     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2008.00982.x     Document Type: Article

References (38)

1. Demyttenaere, K., Bruffaerts, R., Posada-Villa, J., et al. (2004) Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Journal of the American Medical Association, 291 (21 2581 2590.
2. Alonso, J., Angermeyer, M. C., Bernert, S., et al. (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica Suppl. 420 21 27.
3. Sobocki, P., Ekman, M., Agren, H., Krakau, I., Runeson, B., Martensson, B. Jonsson, B. (2007) Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value in Health, 10 (2 153 160.
4. Ustun, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C. Murray, C. J. (2004) Global burden of depressive disorders in the year 2000. Britih Journal of Psychiatry, 184, 386 392.
5. Alonso, J., Angermeyer, M. C., Bernert, S., et al. (2004) Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica Suppl. 420 38 46.
6. Greenberg, P. E., Stiglin, L. E., Finkelstein, S. N. Berndt, E. R. (1993) The economic burden of depression in 1990. Journal of Clinical Psychiatry, 54 (11 405 418.
7. aquinzena 1 6.
8. Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N. Carey, T. S. (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annal of Internal Medicine, 143 (6 415 426.
9. Montgomery, S., Doyle, J. J., Stern, L. McBurney, C. R. (2005) Economic considerations in the prescribing of third-generation antidepressants. Pharmacoeconomics, 23 (5 477 491.
10. Doyle, J. J., Casciano, J., Arikian, S., Tarride, J., Gonzalez, M. A. Casciano, R. (2001) A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value in Health, 4 (1 16 31.
11. Serrano-Blanco, A., Gabarron, E., Garcia-Bayo, I., Soler-Vila, M., Carames-Duran, E., Peñarrubia-Maria, M. T., Pinto-Meza, A. Haro, J. M. (2006) Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. Journal of Affective Disorders, 91 (2-3 153 163.
12. Pirraglia, P. A., Rosen, A. B., Hermann, R. C., Olchanski, N. V. Neumann, P. (2004) Cost-utility analysis studies of depression management: a systematic review. American Journal of Psychiatry, 161 (12 2155 2162.
13. Serrano-Blanco, A., Pinto-Meza, A., Suarez, D., Peñarrubia-Maria, M. T. Haro, J. M. (2006) Cost-utility of mental health interventions for depression in primary care in Catalonia. Acta Psychiatrica Scandinavica, 114 (Suppl. 432 39 47.
14. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J. Stoddart, G. L. (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. New York : Oxford University Press.
15. Neumann, P. J., Stone, P. W., Chapman, R. H., Sandberg, E. A. Bell, C. M. (2000) The quality of reporting in published cost-utility analyses, 1976-1997. Annals of Internal Medicine, 132 (12 964 972.
16. Peveler, R. C., Kendrick, T., Buxton, M., et al. (2005) A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technology Assessment, 9 (16 1 148.
17. Kamlet, M. S., Paul, N., Greenhouse, J., Kupfer, D., Frank, E. Wade, M. (1995) Cost utility analysis of maintenance treatment for recurrent depression. Controlled Clinical Trials, 16 (1 17 40.
18. Lave, J. R., Frank, R. G., Schulberg, H. C. Kamlet, M. S. (1998) Cost-effectiveness of treatments for major depression in primary care practice. Archives of General Psychiatry, 55, 645 651.
19. Hatziandreu, E. J., Brown, R. E., Revicki, D. A., Turner, R., Martindale, J., Levine, S. Siegel, J. E. (1994) Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics, 5 (3 249 268.
20. Revicki, D. A., Brow, R. E., Palmer, W., Bakish, D., Rosser, W., Anton, S. F. Feeny, D. (1995) Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics, 8 (6 524 540.
21. Revicki, D. A., Brow, R. E., Keller, M. B., Gonzales, J., Culpepper, L. Hales, R. E. (1997) Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. Journal of Clinical Psychiatry, 58 (2 47 58.
22. Canadian Coordinating Office for Health Technology Assessment. (1997) Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part II. The cost-effectiveness of SSRIs in treatment of depression. http://www.library. nhs.uk/mentalhealth/viewresource.aspx?resID=252203&tabID=290 (last accessed 12 January 2009)
23. Revicki, D. A., Simon, G. E., Chan, K., Katon, W. Heiligenstein, J. (1998) Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. Journal of Family Practice, 47 (6 446 452.
24. First, M. B., Gibbon, M., Spitzer, R. L. Williams, J. B. W. (2001) Entrevista Clínica Estructurada Para Los Trastornos Del Eje I Del DSM-IV. Barcelona : Masson.
25. Montgomery, S. A. Asberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382 389.
26. Lobo, A., Chamorro, L., Luque, A., Dal-Re, R., Badia, X. Baro, E. (2002) Validación de las versiones en español de la Montgomery-Asberg Depression Rating Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad. Medicina Clinica (Barcelona), 118 (13 493 499.
27. Badia, X., Roset, M., Montserrat, S., Herdman, M. Segura, A. (1999) La versión española de EuroQuol: descripción y aplicaciones. Medicina Clinica (Barcelona), 112 (Suppl. 79 86.
28. Badia, X. (1999) EuroQol, un instrumento para valorar la salud. EQ 5-D guía del usuario, versión española. Medicina Clinica (Barcelona), 114, 6 14.
29. Badia, X., Schiaffino, A., Alonso, J. Herdman, M. (1998) Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Quality of Life Research, 7 (4 311 322.
30. Herdman, M., Badia, X. Berra, S. (2001) El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Atencion Primaria, 28 (6 425 429.
31. Sacristan, J. A., Gilaberte Asin, I., Hylan, T. R., Crown, W. H., Bueno, G., Garzón, M. A. Montejo, A. L. (1999) Costes del tratamiento con nuevos antidepresivos en la práctica clínica. Atencion Primaria, 23, 15 25.
32. SOIKOS. (2001) Base de Datos de Costes sanitarios. Barcelona : Centro de estudios en Economía de la Salud y Política Social.
33. Austin, P. C., Ghali, W. A. Tu, J. V. (2003) A comparison of several regression models for analysing cost of CABG surgery. Statistics in Medicine, 22 (17 2799 2815.
34. Efron, B. Tibshirani, R. J. (1998) An Introduction to the Bootstrap, 2nd edn. Florida : Chapman & Hall / CRC.
35. Iqbal, S. U. Prashker, M. (2005) Pharmacoeconomic evaluation of antidepressants: a critical appraisal of methods. Pharmacoeconomics, 23 (6 595 606.
36. Simon, G. E., Heilingenstein, J. H., Revicki, D. A., Vonkorff, M., Katon, W., Ludman, E., Grothaus, L. Wagner, E. (1999) Long-term outcomes of initial antidepressant drug choice in a 'real world' randomized trial. Archives of Family Medicine, 8 (4 319 325.
37. Anderson, I. M. Tomenson, B. (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal, 310, 1433 1438.
38. Song, F., Freemantl, N., Sheldon, T. A., House, A., Watson, P., Long, A. Mason, J. (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal, 306, 683 687.